The long-range goal of the proposed MIDARP program described in this application is to increase the capacity of Meharry Medical College to conduct rigorous research in drug abuse and addiction with an emphasis on health disparities and clinically underserved populations. The research program will seek to understand the molecular and behavioral basis for the in-vivo responses to acute and chronic methamphetamine (METH) exposures. We also plan to strengthen our intellectual environment and enhance the interest levels of trainees and faculty in drug abuse research.
The Specific Aims of the Meharry Medical College MIDARP Program during the next five years are: 1. To publish at least 10 or more peer-reviewed publications in high-impact journals in drug abuse research;2. To submit 4 or more applications for grants in drug abuse research by year-03 of the proposed award period;3. To acquire 3 or more investigator-initiated awards by the end of year-05;and 4. To stimulate additional faculty and trainee interest in drug abuse research by curricula enhancement, seminars and symposia. One primary and one pilot research projects are proposed, all from junior investigators. In the primary project, Dr. H. Khoshbouei will characterize the biophysical properties of the dopamine transporter in response to METH versus amphetamine in an effort to understand the greater addictive potential of METH. Dr. Chirwa will characterize the impact of prenatal METH exposure on cellular (electrophysiological and molecular) correlates of adult memory and learning. This program will, thus, seek to understand the effect of Methamphetamine on the brain while stimulating the interests of other faculty members and trainees in drug abuse research.
|Yang, Hongyu; Spence, Jeffrey S; Briggs, Richard W et al. (2015) Interaction between early life stress and alcohol dependence on neural stress reactivity. Addict Biol 20:523-33|
|Pandhare, Jui; Addai, Amma B; Mantri, Chinmay K et al. (2014) Cocaine enhances HIV-1-induced CD4(+) T-cell apoptosis: implications in disease progression in cocaine-abusing HIV-1 patients. Am J Pathol 184:927-36|
|Rao, Uma (2014) DSM-5: disruptive mood dysregulation disorder. Asian J Psychiatr 11:119-23|
|Mantri, Chinmay K; Mantri, Jyoti V; Pandhare, Jui et al. (2014) Methamphetamine inhibits HIV-1 replication in CD4+ T cells by modulating anti-HIV-1 miRNA expression. Am J Pathol 184:92-100|
|Eames, Sarah F; Businelle, Michael S; Suris, Alina et al. (2014) Stress moderates the effect of childhood trauma and adversity on recent drinking in treatment-seeking alcohol-dependent men. J Consult Clin Psychol 82:441-7|
|Morris, Matthew C; Kouros, Chrystyna D; Fox, Kathryn R et al. (2014) Interactive models of depression vulnerability: the role of childhood trauma, dysfunctional attitudes, and coping. Br J Clin Psychol 53:245-63|
|Lee, Kiera-Nicole; Pellom, Samuel T; Oliver, Ericka et al. (2014) Characterization of the guinea pig animal model and subsequent comparison of the behavioral effects of selective dopaminergic drugs and methamphetamine. Synapse 68:221-33|
|Rao, Uma (2013) Biomarkers in pediatric depression. Depress Anxiety 30:787-91|
|Swant, Jarod; Goodwin, J Shawn; North, Ashley et al. (2011) ?-Synuclein stimulates a dopamine transporter-dependent chloride current and modulates the activity of the transporter. J Biol Chem 286:43933-43|
|Swant, Jarod; Chirwa, Sanika; Stanwood, Gregg et al. (2010) Methamphetamine reduces LTP and increases baseline synaptic transmission in the CA1 region of mouse hippocampus. PLoS One 5:e11382|
Showing the most recent 10 out of 11 publications